The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts.

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

The new business venture of Spotify founder Daniel Ek – Neko Health – has raised $260 million to bring its full body-scanning ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as ...

In fact, a McKinsey study found that “while 90% of companies have launched some flavour of digital transformation, only a ...

US health insurance giant UnitedHealth Group has appointed company veteran Tim Noel as chief executive of UnitedHealthcare, ...

Purdue Pharma and the Sackler family who own the company have proposed a new $7.4 billion settlement to resolve thousands of ...

Spinraza remains a big product for Biogen, but has seen its sales go into reverse as competition in SMA treatment has emerged ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jennifer Schranz, head of rare diseases at Ipsen, for a ...

BV100 is a new formulation of rifabutin suitable for intravenous administration, which BioVersys claims offers a new ...